

Curriculum Vitae

1104 Kyle Wood Lane, Brandon, Florida 33511 | 4257 West Kennedy Blvd, Tampa, FL 33609 | 11428 N 53rd Street, Temple Terrace, FL 33617
Office 813.948.7550 | MooreCR.com | Fax 813.948.7566

Research & Professional Experience:	
MOORE Clinical Research, Inc., Nurse Practitioner/Clinical Investigator	March 2015-Present
MinuteClinic, Tampa, FL, Family Nurse Practitioner	Sep 2011-April 2015
Galen College of Nursing, Tampa, FL, Adjunct Clinical Instructor	Oct 2013 -Sep 2016
Brandon Regional Hospital, Brandon, FL, Registered Nurse, Critical Care	Oct 1995-May 2004
LifePath Hospice and Palliative Care, Tampa, FL, Registered Nurse	July 2000-Dec 2002
St Mary's Medical Center, Evansville, IN, Registered Nurse, Critical Care	Sep 1994-Sep 1995
Medical Express Staffing, Louisville, KY, Travel Nurse	Nov 1993-June 1995
Carle Foundation Hospital, Urbana, IL, Telemetry Nurse	Jan 1992-Oct 1993

Education:	
University of South Florida, Tampa, FL Master of Science in Nursing, Family Nurse Practitioner	August 2011
Parkland College, Champaign, IL , Associates Applied Science of Nursing	December 1991

Licenses/Certifications:	
Florida Advanced Registered Nurse Practitioner License, ARNP 2769712	July 2020
BLS, Healthcare Provider	October 2019
Bloodborne Pathogens & Biomedical Waste Management 29 CFR OSHA Regulations	June 2018

Training:	
Comprehensive SOP Review	January 2019
Human Subject Assurance Training	December 2018
Adverse Event Collection and Reporting in Clinical Research	May 2018
Comprehensive SOP Review	January 2018
Comprehensive SOP Review	January 2017
Basic HIPAA Training	January 2017
GCP Training, NIH	October 2016
National Academy of Dermatology & American College of Dermatology Nurse Practitioners 5 th Annual Conf	May 2016
Comprehensive SOP Review	January 2016
Clinical Investigator GCP & Trials Management Conference, SoCRA	December 2015
Rosacea Clinical Assessment Training	August 2015
Atopic Dermatitis Clinical Assessment Training	August 2015
Plaque Psoriasis Clinical Assessment Training	August 2015
Actinic Keratosis Clinical Assessment Training	August 2015
Acne Lesion Count, IGA and Severity Training & Validation	June 2015
Biomedical Waste Management & Blood borne Pathogens Training	April 2015
Mycology Certification Training (Specimen Collection, KOH Interpretation, Differential)	April 2015
Phlebotomy Fundamentals Anderson Continuing Education	April 2015
Good Documentation Practices	March 2015
Adverse Events (Determination and Reporting)	March 2015
Clinical Assessments of Acne Vulgaris (IGA and lesion count)	March 2015

Curriculum Vitae

1104 Kyle Wood Lane, Brandon, Florida 33511 | 4257 West Kennedy Blvd, Tampa, FL 33609 | 11428 N 53rd Street, Temple Terrace, FL 33617
Office 813.948.7550 | MooreCR.com | Fax 813.948.7566

Clinical Assessments of Plaque Psoriasis	March 2015
In-House Introduction to GCP	March 2015

Brief Summary of Skills & Relevant Experience:

Customer Service, Recruitment, Informed Consent Process, Screening Procedures, UPT Processing & Resulting, Vital Signs, Phlebotomy, PK Sampling, ECGs, KOH Sampling, Processing & Resulting, Physical Exams, Photography, Quality Assurance & Control Procedures, Assessments for: Acne Vulgaris, Rosacea, Actinic Keratosis, Atopic Dermatitis, Tinea Pedis, Onychomycosis, Plaque Psoriasis, Scalp Psoriasis, Herpes Simplex; Protocol Eligibility, Patient Safety Evaluations

Signature

Date

Clinical Trial Experience:

- ACNE VULGARIS (Validated Acne Rater)

"A Multi-Center, Double-Blind, Randomized, Placebo Controlled, Parallel-Group Study, Comparing Clindamycin Phosphate Topical Lotion 1% (XXXX) to Clindamycin Phosphate Topical Lotion 1% (XXXX) and Both Active Treatments to a Placebo Control in the Treatment of Acne Vulgaris." 2019

"A Phase 3 Multi-Center, Double-Blind, Randomized, Vehicle Controlled Study of XXXX in the Treatment of Acne Vulgaris." 2019

"A Multi-Center, Double-Blind, Randomized, Three-Arm, Placebo Controlled, Parallel-Group Study, Comparing Dapsone Gel, 7.5% (XXXX) to Aczone® (Dapsone) Gel, 7.5% (XXXX) and Both Active Treatments to A Placebo Control in the Treatment of Acne Vulgaris." 2019

"A Phase 2, Randomized, Multicenter, Double-Blind, Vehicle Controlled, Dose-ranging Study to Evaluate the Efficacy and Safety of VB-1953 Topical Gel When Applied Daily for 12 Weeks in Subjects with Facial Acne Vulgaris for Treatment of Moderate to Severe Inflammatory Acne Vulgaris" 2019

"A Multi-Center, Double-Blind, Randomized, Placebo Controlled, Parallel-Group Study, Comparing Clindamycin Phosphate Topical Gel 1% (XXXX) to Cleocin T (Clindamycin Phosphate Topical Gel 1% XXXX) and Both Active Treatments to a Placebo Control in the Treatment of Acne Vulgaris." 2019

"A Multi-Center, Double-Blind, Randomized, Vehicle-Controlled, Parallel-Group Study, Comparing Clindamycin 1% to Cleocin T (XXXX, Clindamycin 1% Gel) and Both Active Treatments to a Vehicle Control in the Treatment of Acne." 2018

"A Randomized, Double-Blind, Vehicle-Controlled Study to Evaluate the Efficacy and Safety of Topical Administration of FMX101 for 12 Weeks in the Treatment of Moderate-to-Severe Acne Vulgaris." 2018

"A Multicenter, Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Comparison Study to Evaluate the Safety and Efficacy of UHE-101 Cream 1% When Applied Twice Daily for 12 Weeks in Subjects with Facial Acne Vulgaris." 2017

"A Multi-Center, Double-Blind, Randomized, Placebo Controlled Parallel-Group Study, Comparing Tretinoin Cream, 0.1% (XXXX) to Retin-A® (Tretinoin) Cream, 0.1% (XXXX) and Both Active Treatments to a Placebo Control in the Treatment of Acne Vulgaris." 2017

"A Multi-Center, Double-Blind, Randomized, Placebo Controlled Parallel-Group Study, Comparing Tretinoin Cream, 0.05% (XXXX) to Retin-A® (Tretinoin) Cream, 0.05% (XXXX) and Both Active Treatments to a Placebo Control in the Treatment of Acne Vulgaris." 2017

Curriculum Vitae

1104 Kyle Wood Lane, Brandon, Florida 33511 | 4257 West Kennedy Blvd, Tampa, FL 33609 | 11428 N 53rd Street, Temple Terrace, FL 33617
Office 813.948.7550 | MooreCR.com | Fax 813.948.7566

"A Multicenter, Randomized, Double Blind, Parallel, Placebo Controlled, Clinical Endpoint Study to Determine the Therapeutic Equivalence of Test Product Benzoyl Peroxide (5%) + Clindamycin Phosphate (Equivalent to 1% Base) Gel and Reference Product BenzaClin® Topical Gel in Patients with Acne Vulgaris." 2017

"A Multi-Center, Double-Blind, Randomized, Placebo Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Adapalene Spray, 0.3% in the Treatment of Acne Vulgaris." 2016

"A Multi-Center, Double-Blind, Randomized, Placebo Controlled, Parallel-Group Study, Comparing Dapsone Gel, 7.5% (XXXX) to Aczone (Dapsone) Gel, 7.5%, XXXX, and Both Active Treatments to a Placebo Control in the Treatment of Acne Vulgaris." 2016

"A Phase 2, Randomized, Multicenter, Double-Blind, Active and Vehicle Controlled Parallel-group Study Evaluating the Efficacy, Safety, and Tolerability of Products XXXX and XXXX for the Treatment of Acne Vulgaris for 12 Weeks." 2016

"A Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study Comparing Dapsone 5% Gel, (XXXX) to Aczone® (XXXX Dapson Gel 5%) and Both Active Ingredients Compared to Placebo (Vehicle) in the Treatment of Acne Vulgaris." 2016

"A Randomized, Double-Blind, Placebo-Controlled, Parallel-Design, Multiple-Site Clinical Study to Evaluate the Therapeutic Equivalence and Safety of adapalene and benzoyl peroxide gel, 0.3%/2.5% (Actavis Laboratories UT, Inc.) to Epiduo® Forte (adapalene and benzoyl peroxide) gel 0.3%/2.5% (Galderma) in the treatment of Acne Vulgaris." 2015

"A Multi-Center, Double-Blind, Randomized, Placebo Controlled, Parallel Group Study, Comparing Dapsone Gel, 5% (XXX) to Aczone® (Dapsone) Gel, 5%, (XXXX) and Both Active Treatments to a Placebo Control in the Treatment of Acne Vulgaris." 2015

"A Multi-Center, Double-Blind, Randomized, Placebo Controlled, Parallel Group Study, Comparing Clindamycin and Benzoyl Peroxide Gel 1%/5% (XXXX Pharmaceuticals, Inc.) to Benzaclin® (Clindamycin, as Phosphate, 1% and Benzoyl Peroxide 5%) Topical Gel (XXXX) and Both Active Treatments to a Placebo Control in the Treatment of Acne Vulgaris." 2015

"A Multi-Center, Double-Blind, Randomized, Placebo Controlled, Parallel-Group Study, Comparing Adapalene and Benzoyl Peroxide Gel, 0.35/2.5% (XXXX Pharmaceuticals USA, Inc.) to Epiduo® Forte (Adapalene and Benzoyl Peroxide Gel 0.3%/2.5%, XXXX Laboratories, L.P.) and Both Active Treatments to a Placebo Control in the Treatment of Acne Vulgaris." 2015

"A Double-Blind, Randomized, Placebo Controlled Dose-Ranging Study Evaluating the Efficacy and Safety of Once Weekly High Dose Oral Finasteride in the Treatment of Severe Nodulocystic Acne." 2015

"A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multiple-Site Study to Evaluate the Therapeutic Equivalence of a Generic Clindamycin 1%/Benzoyl Peroxide 5% Topical Gel (XXXX) to the Marketed Product BenzaClin® Topical Gel, Clindamycin 1%/Benzoyl Peroxide 5% (XXXX) in the Treatment of Acne Vulgaris." 2015

"A Multi-Center, Double-Blind, Randomized, Placebo Controlled, Parallel-Group Study, Comparing Clindamycin and Benzoyl Peroxide Gel 1.2%/3.75% (XXXX Pharmaceuticals, Inc.) to Onexton™ Gel (Clindamycin and Benzoyl Peroxide Gel 1.2%/3.75% XXXX Pharmaceuticals LLC) and Both Active Treatments to a Placebo Control in the Treatment of Acne Vulgaris." 2015

A Multi-Center, Double-Blind, Randomized, Placebo Controlled, Parallel-Group Study, Comparing Adapalene and Benzoyl Peroxide Gel 0.1%/2.5% (XXXX Pharmaceuticals, Inc.) to Tactupump™ (XXXX Inc., Adapalene and Benzoyl Peroxide Topical Gel, 0.1%/2.5% w/w) and Both Active Treatments to a Placebo Control in the Treatment of Acne Vulgaris." 2015

XXXX Acne Product Study for the Alleviation of Facial Acne and Associated Redness and Inflammation

"A single-site, randomized, single-blind, comparative therapeutic clinical study against open-label Proactiv+®" 2015

Curriculum Vitae

1104 Kyle Wood Lane, Brandon, Florida 33511 | 4257 West Kennedy Blvd, Tampa, FL 33609 | 11428 N 53rd Street, Temple Terrace, FL 33617
Office 813.948.7550 | MooreCR.com | Fax 813.948.7566

- ROSACEA

"A Phase 3 Multi-Center, Double-Blind, Randomized, Vehicle-Controlled Study of XXXX in the Treatment of Papulopustular Rosacea." 2018

"A Multi-Center, Double-Blind, Randomized, Placebo Controlled, Parallel-Group Study, Comparing Azelaic Acid Foam 15% (XXXX) to Finacea (XXXX) and Both Active Treatments to a Placebo Control in the Treatment of Moderate Facial Rosacea." 2017

"A Multi-Center, Double-Blind, Randomized, Placebo Controlled, Parallel-Group Study, Comparing Ivermectin Cream 1% (XXXX) to Soolantra® (XXXX) and Both Active Treatments to a Placebo Control in the Treatment of Moderate to Severe Facial Rosacea." 2017

"A Multi-Center, Double-Blind, Randomized, Placebo Controlled, Parallel-Group Study, Comparing Azelaic Acid Topical Gel 15% (XXXX Pharmaceuticals USA, Inc) to Finacea Gel (XXXX) and Both Active Treatments to a Placebo Control in the Treatment of Moderate Facial Rosacea." 2016

"A Multicenter, Double-blind, Randomized, Parallel-group, Vehicle-Controlled Study to Evaluate the Safety and Clinical Equivalence of a Generic Azelaic Acid Foam, 15% and the Reference Listed Finacea® (Azelaic acid) Foam, 15% in Patients with Moderate Facial Rosacea." 2016

- PSORIASIS

"A Multi-Center, Double-Blind, Randomized, Placebo Controlled, Parallel-Group Study, Comparing Calcipotriol and Betamethasone Dipropionate Topical Gel 0.005%/0.064% (XXXX) Dovobet® Gel (Calcipotriol and Betamethasone Dipropionate Gel) 0.005%/0.064% (XXXX) and Both Active Treatments to a Placebo Control in the Treatment of Mild to Moderate Body Plaque Psoriasis Vulgaris." 2018

"A Double-Blind, Randomized, Multicenter, Vehicle Controlled, Parallel Group Comparison Study to Determine the Efficacy and Safety of Halobetasol Propionate Spray, 0.05% Versus Vehicle Spray in Subjects with Plaque Psoriasis Receiving Up to Four Weeks of Twice Daily Treatment." 2018

"A Randomized, Double-Blind, Placebo-Controlled, Multicenter, 24-Week Study to Assess the Efficacy and Safety of PPC-06 (Tepilamide Fumarate) Extended Release Tablets in Subjects with Moderate-to-Severe Plaque Psoriasis." 2018

"A Multi-Center, Double-Blind, Randomized, Vehicle Controlled, Parallel-Group Study Comparing Tazarotene Cream 0.05% to TAZORAC® (tazarotene) Cream 0.05% and Both Active Treatments to a Vehicle Control in the Treatment of Stable Plaque Psoriasis." 2016

"A Randomized, Double-Blind, Vehicle-Controlled, Multicenter, Parallel Group Study of the Efficacy and Safety of DFD-06 Cream in the Treatment of Moderate to Severe Plaque Psoriasis for 14 Days." 2016

"A Randomized, Double-Blind, Placebo-Controlled, Parallel-Design, Multiple-Site Clinical Study to Evaluate the Efficacy and Safety of Desoximetasone Topical Spray, 0.15% (XXX Pharmaceuticals, U.S.A., Inc.) in Patients with Mild to Moderate Plaque Psoriasis." 2015

"A Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study, Comparing Tazarotene Cream 0.05% (XXXX Pharmaceuticals, Inc.) to Tazorac (XXXX, LLC, Tazarotene Cream 0.05% and Both Active Treatments to a Placebo Control in the Treatment of Plaque Psoriasis." 2014

- SCALP PSORIASIS

"A Multi-Center, Double-Blind, Randomized, Placebo Controlled, Parallel-Group Study, Comparing Calcipotriene Hydrate and Betamethasone Dipropionate Topical Suspension 0.005%/0.064% (XXXX) to Talconex® (Calcipotriene Hydrate and Betamethasone Dipropionate) Topical Suspension 0.005%.0.064% (XXXX) and Both Active Treatments to a Placebo Control in the Treatment of Scalp Psoriasis." 2018

"A Randomized, Double-blind, Parallel-group, Vehicle-controlled, Multicenter Study Comparing XXXX Calcipotriene Hydrate and Betamethasone Dipropionate Topical Suspension 0.005%/0.064% to Reference Listed Drug in the Treatment of Scalp Psoriasis." 2017

Curriculum Vitae

1104 Kyle Wood Lane, Brandon, Florida 33511 | 4257 West Kennedy Blvd, Tampa, FL 33609 | 11428 N 53rd Street, Temple Terrace, FL 33617
Office 813.948.7550 | MooreCR.com | Fax 813.948.7566

- ATOPIC DERMATITIS

"A Multi-Center, Double-Blind, Randomized, Placebo Controlled, Parallel-Group Study, Comparing Doxepin Hydrochloride Topical Cream, 5% (XXXX) to Doxepin Hydrochloride topical cream, 5% (XXXX) and Both Active Treatments to a Placebo Control in the Treatment of Moderate Pruritis in Adults with Atopic Dermatitis." 2019

- TINEA PEDIS

"A Randomized, Double-Blind, Vehicle-Controlled, Parallel-Design, Multiple-Site Study to Evaluate the Therapeutics Equivalence of Ketoconazole Cream 2% (XXXX) to Ketoconazole 2% (XXXX) in the Treatment of Tinea Pedis." 2019

"A Multi-Center, Double-Blind, Randomized, Placebo Controlled, Parallel-Group Study, Comparing Clotrimazole and Betamethasone Dipropionate Cream 1%/0.064% (XXXX) to Lotriderm (Clotrimazole and Betamethasone Dipropionate) Cream 1%/0.064% (XXXX) and Both Active Treatments to a Placebo Control in the Treatment of Tinea Pedis." 2018

"A Multi-Center, Double-Blind, Randomized, Placebo Controlled, Parallel Group Study, Comparing Naftifine HCL Gel 2% (XXXX) to Naftin (Naftifine HCL) Gel, 2% (XXXX) and Both Active Treatments to a Placebo Control in the Treatment of Tinea Pedis." 2017

"A Multi-Center, Double-Blind, Randomized, Placebo Controlled, Parallel-Group Study, Comparing Luliconazole Cream 1% (XXXX) to Luzu (Luliconazole) Cream, 1% (XXXX) and Both Active Treatments to a Placebo Control in the Treatment of Tinea Pedis." 2017

"A Randomized, Prospective Multicenter, Double Blind, Parallel Assignment, Placebo Controlled, Bioequivalence Study of Naftifine Hydrochloride Cream, 2% for Topical Use with that of Naftifine (naftifine hydrochloride) Cream 2% for Topical Use in Patients with Tinea Pedis Using Clinical Endpoints." 2015

- ONYCHOMYCOSIS

"A Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Multi-Site Phase 2b Clinical Study to Assess the Efficacy, Safety and Tolerability of 8-Week Regimens of Novexatin[®], 10% Topical Solution (XXXX, USA, Inc.) in Patients with Mild to Moderate Onychomycosis." 2016

- INFLUENZA

"A Phase III, Randomized, Double-Blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Nitazoxanide in the Treatment of Uncomplicated Influenza." 2018

"A Clinical Study to Demonstrate the Clinical Significance and Effectiveness of a Combination of Tamiflu[®] (Oseltamivir Phosphate) and XXX 351 versus Tamiflu[®] (Oseltamivir Phosphate) Alone as a Treatment for Influenza *and* the Effectiveness of a Recommended Prevention Dose of Tamiflu[®] (Oseltamivir Phosphate) Alone versus a Treatment of Tamiflu (Oseltamivir Phosphate) in Combination with XXX 351 as a Treatment for the Prevention of Influenza." 2015

- OSTEOARTHRITIS

"A Multi-Center, Double-Blind, Randomized, Placebo Controlled, Parallel-Group Study, Comparing Diclofenac Sodium Gel, 1% (XXXX) to Voltaren Gel (Diclofenac Sodium) Gel, 1% (XXXX) and Both Active Treatments to a Placebo Control in the Treatment of Patients with Osteoarthritis of the Knee." 2017

"XXXX Product Study for the Alleviation of Pain, Inflammation and Increased Range of Motion in Patients Diagnosed with Mild to Moderate Knee Osteoarthritis; A Single-Site, Randomized, Double-Blind, Placebo-Controlled Comparative Therapeutic Clinical Study Against Osteo Bi-Flex Triple Strength." 2016

Curriculum Vitae

1104 Kyle Wood Lane, Brandon, Florida 33511 | 4257 West Kennedy Blvd, Tampa, FL 33609 | 11428 N 53rd Street, Temple Terrace, FL 33617
Office 813.948.7550 | MooreCR.com | Fax 813.948.7566

- GLUCOSE RISK ASSESSMENT DEVICE

“Glucose Risk Assessment in Employer Populations” 2019, Principal Investigator